AbbVie Inc. is a global, diversified research-based biopharmaceutical company that develops and markets advanced therapies for complex and serious diseases. The company operates as a single global business segment focused on the research, development, manufacturing, and commercialization of medicines across four primary therapeutic areas: immunology, neuroscience, oncology, and aesthetics. Its immunology portfolio includes Skyrizi, Rinvoq, and Humira, which treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In neuroscience, AbbVie offers Vraylar for schizophrenia and bipolar disorder, Botox Therapeutic for spasticity and chronic migraine, and migraine-specific treatments Ubrelvy and Qulipta. The company serves patients in North America, the European Union, Japan, and numerous other markets worldwide. AbbVie was founded in 2012 and became an independent, publicly-traded company on January 1, 2013, following the distribution of its shares by Abbott Laboratories.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage abbvie.com
Sector Healthcare IR page news.abbvie.com
Tags
biopharmaceuticals, immunology, neuroscience, oncology, aesthetics, autoimmune diseases, rheumatology, dermatology, gastroenterology, migraine, schizophrenia, bipolar disorder, Skyrizi, Rinvoq, Humira, Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev, Aquipta
Press page —

Metrics

Valuation  
Market cap $ 518.972B
Market cap (USD) $ 518.972B
P/E 50.53
PEG —
P/BV -113.24
P/S 7.86
P/OCF 25.83
P/FCF 27.50
Dividend yield 2.4%
Turnover / mcap —
Returns  
ROE -129.2%
ROI 6.1%
ROIC 13.9%
Profit margin 6.9%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -29.2%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 54
Quality score -10.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 61.16B 56.334B 54.318B 58.054B 56.197B 45.804B 33.266B 32.753B 28.216B 25.638B 22.859B 19.96B 18.79B 18.38B
Net profit 4.226B 4.278B 4.863B 11.836B 11.542B 4.616B 7.882B 5.687B 5.309B 5.953B 5.144B 1.774B 4.128B 5.275B
Free cash flow 17.816B 17.832B 22.062B 24.248B 21.99B 16.79B 12.772B 12.789B 9.431B 6.562B 7.003B 2.937B 5.776B 6.012B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 228.49 177.7 154.97 161.61 135.4 107.15 88.54 92.19 96.71 62.62 59.24 65.44 52.81 34.19
Price performance 12m 0.29 0.15 -0.04 0.19 0.26 0.21 -0.04 -0.05 0.54 0.06 -0.09 0.24 0.54 -0.75

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 4.76B 5.09B 5.38B 5.43B 8.82B 9.98B 11.3B 11.2B 10.9B 12.6B
↳ YoY growth +0.6% +6.9% +5.8% +0.8% +62.5% +13.1% +12.8% -0.9% -2.1% +15.3%
↳ 5y CAGR +4.5% +7.2% +13.3% +16.0% +17.2% +15.7% +15.0% +7.4%
Borrowings, current (USD) 377M 400M 3.7B 0.00 34M 14M 1M 0.00 6.8B 2.5B
Borrowings, non-current (USD) 36.4B 31B 35B 63B 77.6B 64.2B 59.1B 52.2B 60.3B 58.9B
Lease liabilities (USD) — — — 360M 1.01B 925M 954M 943M 915M 924M
Cash and deposits (USD) 5.1B 9.3B 7.29B 39.9B 8.45B 9.75B 9.2B 12.8B 5.52B 5.23B
Intangible assets (USD) 28.9B 27.6B 21.2B 18.6B 82.9B 76B 67.4B 55.6B 60.1B 52.6B
Right-of-use assets (USD) — — — — 895M 762M 737M 744M 723M 737M
Net debt (borrowings + leases - cash) (USD) 31.7B 22.1B 31.4B 23.4B 70.1B 55.4B 50.9B 40.3B 62.5B 57.1B
Cash flow detail
Operating cash flow (USD) 7.04B 9.96B 13.4B 13.3B 17.6B 22.8B 24.9B 22.8B 18.8B 19B
Purchases of property, plant and equipment (USD) -479M -529M -638M -552M -798M -787M -695M -777M -974M -1.21B
Change in receivables (cash effect) (USD) -71M -391M -591M -74M -929M -1.32B -1.46B 66M 207M -1.49B
Change in inventories (cash effect) (USD) -38M 93M -226M -231M -40M -142M -686M -417M -319M -234M
Change in payables (cash effect) (USD) -1.19B 425M 190M -1.12B 1.51B 1.63B 1.61B 3.84B 177M 951M
Dividends paid (cash effect) (USD) -3.72B -4.11B -5.58B -6.37B -7.72B -9.26B -10B -10.5B -11B -11.7B
Share buybacks (cash effect) (USD) -6.03B -1.41B -12B -629M -978M -934M -1.49B -1.97B -1.71B -980M
Interest paid (cash effect) (USD) -986M -1.1B -1.22B -1.79B -2.62B -2.71B -2.55B -2.47B -2.81B -3B
Income taxes paid (cash effect) (USD) -3.56B -1.7B — -1.45B -1.67B -3.65B -2.99B -4.7B -4.06B -3.63B
Share-based compensation (USD) 353M 365M 421M 430M 753M 692M 671M 747M 911M 955M
Operating cash flow before change in receivables (USD) 7.11B 10.4B 14B 13.4B 18.5B 24.1B 26.4B 22.8B 18.6B 20.5B
Free cash flow (OCF - PPE - intangibles) (USD) 6.56B 9.43B 12.8B 12.8B 16.8B 22B 24.2B 22.1B 17.8B 17.8B
Income detail
Research and development expense (USD) 4.37B 4.98B 10.3B 6.41B 6.56B 7.08B 6.51B 7.68B 12.8B 9.1B
↳ 5y CAGR +10.8% +12.4% +29.3% +14.2% +8.9% +10.2% +5.5% -5.8% +14.8% +6.8%
Total comprehensive income (USD) 5.93B 5.17B 5.93B 6.77B 5.1B 11.8B 12.5B 4.77B 4.67B 5.01B
Comprehensive income to owners (USD) 5.93B 5.17B 5.93B 6.77B 5.1B 11.8B 12.5B 4.76B 4.66B 5.01B
Reported May 5, 2017 May 4, 2018 Feb 27, 2019 Feb 21, 2020 Feb 18, 2022 Feb 18, 2022 Feb 17, 2023 Feb 20, 2024 Feb 14, 2025 Feb 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 03, 2026

– Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial outcomes
– A digital image analysis evaluating glabellar line severity and brow position following treatment with investigational trenibotulinumtoxinE (trenibotE) and BOTOX®
Cosmetic (onabotulinumtoxinA) will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session_– Expert panel to explore shifting consumer expectations, common misconceptions and medical weight loss in aesthetics, drawing on insights from the Allergan Aesthetics "What Consumers Really Want" report_

IRVINE, Calif., Nov. 3, 2026 /PRNewswire / -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, Nov. 5-8 in San Diego, underscoring the company's continued investment in generating scientific evidence to inform care across multiple aesthetic categories. The presentations include new data from two Phase 4 studies examining aesthetic treatment in patients on glucagon-like peptide-1 (GLP-1)-related medications for weight management, with a focus on patient satisfaction and psychosocial outcomes. Additional presentations span multimodal aesthetic treatment across diverse patient populations, neurotoxin innovation, body contouring and skin quality, including exosome research.

"Advancing aesthetic medicine starts with understanding patients' evolving needs and generating the scientific evidence to keep pace," said Darin Messina, Ph.D., senior vice president, head of aesthetics research and development, AbbVie. "We continue to build on our extensive body of clinical research, including studies of multimodal treatment approaches, to help providers make informed decisions about using our products to address a range of aesthetic concerns."

Two video oral abstract presentations will share new data from Phase 4 studies exploring aesthetic treatment in patients taking GLP-1-related medications for weight loss, with research examining facial appearance, skin quality, patient satisfaction and psychosocial outcomes:

  • HARMONY IN DIVERSITY: Improved Satisfaction With Aesthetic Appearance and Psychosocial Function Following Multimodal Aesthetic Treatment in a Medical Weight Loss Cohort 
  • Satisfaction With Overall Facial Appearance and Psychological Outcomes After Treatment With Hyaluronic Acid Injectables in Patients With Medical Weight Loss 

"Patients experiencing medical weight loss may have aesthetic concerns that extend beyond changes in facial volume or skin quality," said Joely Kaufman-Janette, M.D., board-certified dermatologist, Skin Research Institute, and study investigator. "By examining patient satisfaction and psychosocial well-being alongside changes in physical appearance, we can gain a more complete picture of their needs and support them with individualized treatment approaches throughout their aesthetic journeys."

A digital image analysis of glabellar line severity and brow position following treatment with investigational trenibotE and BOTOX® Cosmetic will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session at 7:30 a.m. PT on Sunday, Nov. 8. The analysis uses objective digital imaging to add quantitative measures that complement clinician assessment.

  • Similar Clinical Outcomes in Glabellar Line Severity and Brow Position Following TrenibotE and OnabotA Treatment: A Digital Image Analysis (presented by Jean Carruthers, M.D. on behalf of Shannon Humphrey, M.D.)

Allergan Aesthetics will also host The Aesthetics Evolution: Inside the Changing Consumer Landscape expert panel at 12:30 p.m. PT on Thursday, Nov. 5, in the Special Events Room. Drawing on insights from the company's "What Consumers Really Want" report, the panel will examine shifting consumer expectations, common misconceptions and medical weight loss in aesthetics. Tiffany Libby, M.D., will moderate the panel, featuring Anthony Rossi, M.D.; Joely Kaufman-Janette, M.D.; and Vince Bertucci, M.D.

Other presentations from Allergan Aesthetics highlight new data on multimodal aesthetic treatment of the face and neck across a diverse patient population, including patient-reported satisfaction and psychosocial outcomes; the use of a topical cosmetic human fibroblast-derived exosome serum to support skin quality, both as part of a daily skincare regimen and alongside in-office procedures such as radiofrequency microneedling, non-ablative laser and diamond tip microdermabrasion; and how treatment sequence may influence outcomes and patient experience when combining cryolipolysis and electromagnetic muscle stimulation for abdominal body contouring.

A full list of Allergan Aesthetics' presentations is below.

Title Authors Format
Medical Weight Loss
Satisfaction With Overall Facial Appearance and Psychological Outcomes After Treatment With Hyaluronic Acid Injectables in Patients With Medical Weight Loss Sabrina Fabi, M.D.; Jeremy B. Green, M.D.; Katherine Zibilich Holcomb, M.D.; Kian Karimi, M.D.; Sarah Jackson, M.D.; Julie Garcia; Hongsuk Song; Carinna Kison; Nazanin Ashourian, Ph.D. Video Oral Abstract
HARMONY IN DIVERSITY: Improved Satisfaction With Aesthetic Appearance and Psychosocial Function Following Multimodal Aesthetic Treatment in a Medical Weight Loss Cohort Joely Kaufman-Janette, M.D.; Craig Teller, M.D.; Terrence Keaney, M.D.; Amir Moradi, M.D.; Elena Dimitrijevic, Ph.D.; Warren Tong; Nazanin Ashourian, Ph.D.; Lynn Zhang; Amy Weitzenfeld, M.D.; Helena Pavicic; Sachin Shridharani, M.D. Video Oral Abstract
TrenibotE (Cosmetic Oral Abstract Presentations: Top Ten)
Similar Clinical Outcomes in Glabellar Line Severity and Brow Position Following TrenibotE and OnabotA Treatment: A Digital Image Analysis Shannon Humphrey, M.D.; Jean Carruthers, M.D.; Terrence Keaney, M.D.; Sachin Shridharani, M.D.; Emily McCusker, Ph.D.; Siavash Mortezavi; Maria Musumeci, Ph.D.; Rafael Tuazon; Elena Dimitrijevic, Ph.D. Oral Presentation
Multimodal Treatment
HARMONY IN DIVERSITY: Positive Impact of Multimodal Aesthetic Treatment of the Face and Neck on Patient-Reported Satisfaction With Appearance and Psychosocial Function Cheryl Burgess, M.D.; Charles Boyd, M.D.; Deirdre Hooper, M.D.; Keith Marcus, M.D.; Nazanin Ashourian, Ph.D.; Warren Tong; Helena Pavicic; Lynn Zhang; Amy Weitzenfeld, M.D.; Elena Dimitrijevic, Ph.D.; Younghoon Cho, M.D. Video Oral Abstract
Skincare/Exosomes
A Topical Fibroblast-Derived Exosomes Serum Improved Skin Quality Parameters in Premenopausal and Postmenopausal Women: Results From a 12-Week Study Shannon Humphrey, M.D.; Priscilla Huang; Elizabeth Makino; Tsing Cheng, Ph.D.; Nana Thompson, Ph.D.; Prithwiraj Maitra, Ph.D. Video Oral Abstract
Efficacy of a Topical Skincare Regimen Including Cosmetic Human Fibroblast-Derived Exosome Serum and Growth Factor Serum: A Multisite Study Edward Lain, M.D.; Priscilla Huang; Elizabeth Makino; Tsing Cheng, Ph.D.; Nancy D. Rodgers, Ph.D.; Prithwiraj Maitra, Ph.D. Video Oral Abstract
Topical Cosmetic Human Fibroblast-Derived Exosomes Serum Helps Support Radiofrequency Microneedling or Non-Ablative Laser Treatment Recovery and Rejuvenation Benefits Saami Khalifian, M.D.; Jessica Shisler, Ph.D.; Elizabeth Makino; Priscilla Huang; Tsing Cheng, Ph.D.; Prithwiraj Maitra, Ph.D. Video Oral Abstract
Skin Quality Improvements Following Diamond Tip Microdermabrasion With Exosome Serum and Topical Exosome Skincare Before and After Cosmetic Neurotoxin Treatment Amelia Hausauer, M.D.; Lisa T. Goberdhan; Katie Schneider; Arielle Bautista; Tsing Cheng, Ph.D.; Elizabeth Makino Video Oral Abstract
Body Contouring
Safety and Effectiveness of Two Sequencing Strategies Combining Cryolipolysis and Electromagnetic Muscle Stimulation for Abdominal Body Contouring Amy Taub, M.D.; Elana Block; Christopher Tokarczyk; Agnesa Avanesian, Ph.D. Video Oral Abstract

BOTOX**®** Cosmetic (onabotulinumtoxinA) Important Information

Indications

BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:
- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- Moderate to severe lateral canthal lines associated with orbicularis oculi activity
- Moderate to severe forehead lines associated with frontalis activity
- Moderate to severe platysma bands associated with platysma muscle activity

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING 

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

CONTRAINDICATIONS

BOTOX**®** Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS
Lack of Equivalency Between Botulinum Toxin Products
The potency Units of BOTOX®
Cosmetic are specific to the preparation and assay method utilized. BOTOX
®
Cosmetic is not equivalent to other preparations of botulinum toxin products, and therefore, Units of biological activity of BOTOX**®** Cosmetic cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method.

**Spread of Toxin Effect
**Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX**®** Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX®
 injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX**®** to the site of injection and/or adjacent structures. In several of the cases, patients had preexisting dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX**®. The safety and effectiveness of BOTOX®** for unapproved uses have not been established.

**Hypersensitivity Reactions
**Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such a reaction occurs, discontinue further injection of BOTOX Cosmetic and immediately institute appropriate medical therapy. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Cardiovascular System
There have been reports following administration of BOTOX®
 of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors, including preexisting cardiovascular disease. Use caution when administering to patients with preexisting cardiovascular disease.

**Increased Risk of Clinically Significant Effects With Preexisting Neuromuscular Disorders
**Patients with neuromuscular disorders may be at increased risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions). Monitor individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) when given botulinum toxin.

Dysphagia and Breathing Difficulties
Treatment with BOTOX®
 and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with preexisting swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see Boxed Warning).

Preexisting Conditions at the Injection Site
Use caution when BOTOX®
 Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

Dry Eye in Patients Treated With BOTOX**®** CosmeticThere have been reports of dry eye associated with BOTOX**®** Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

**Human Albumin and Transmission of Viral Diseases
**This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), which would also be considered remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS
The most frequently reported adverse reactions following injection of BOTOX®
 Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).

The most frequently reported adverse reaction following injection of BOTOX**®** Cosmetic for lateral canthal lines was eyelid edema (1%).

The most frequently reported adverse reactions following injection of BOTOX**®** Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%).

The safety profile of BOTOX**®** Cosmetic treatment of platysma bands is consistent with the known safety profile of BOTOX**®** Cosmetic for other indications.

DRUG INTERACTIONS
Coadministration of BOTOX®
 Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX**®** Cosmetic may potentiate systemic anticholinergic effects.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX**®** Cosmetic.

USE IN SPECIFIC POPULATIONS
There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX®
 Cosmetic in pregnant women. There are no data on the presence of BOTOX**®** Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.

Please see BOTOX**®** Cosmetic full Prescribing Information , including Boxed Warning and Medication Guide .

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com .

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on LinkedIn,  Facebook , Instagram , X  and YouTube.

Forward-Looking Statements  

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

Media Contact: Tracy Garcia Gale +1 (657) 831-9499 [email protected] Investor Relations: Liz Shea +1 (847) 935-2211 [email protected]

Allergan Aesthetics

SOURCE AbbVie

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

AbbVie Reports Third-Quarter 2026 Financial Results Bull 6 Bear 0 Results

October 30, 2026

  • Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an Unfavorable Impact of $0.11 Per Share Related to Acquired IPR&D and Milestones Expense 

  • Delivers Third-Quarter Net Revenues of $17.404 Billion, an Increase of 10.3 Percent on a Reported Basis or 10.5 Percent on an Operational Basis

  • Third-Quarter Global Net Revenues from the Immunology Portfolio Were $9.165 Billion, an Increase of 16.3 Percent on a Reported Basis, or 16.6 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $5.776 Billion; Global Rinvoq Net Revenues Were $2.706 Billion; Global Humira Net Revenues Were $683 Million

  • Third-Quarter Global Net Revenues from the Neuroscience Portfolio Were $3.389 Billion, an Increase of 19.4 Percent on a Reported Basis, or 19.5 Percent on an Operational Basis; Global Vraylar Net Revenues Were $1.068 Billion; Global Botox Therapeutic Net Revenues Were $1.080 Billion; Combined Global Ubrelvy and Qulipta Net Revenues Were $847 Million; Global Vyalev Net Revenues Were $286 Million

  • Third-Quarter Global Net Revenues from the Oncology Portfolio Were $1.696 Billion, an Increase of 0.8 Percent on a Reported Basis, or 0.9 Percent on an Operational Basis; Global Venclexta Net Revenues Were $803 Million; Global Imbruvica Net Revenues Were $522 Million; Global Elahere Net Revenues Were $224 Million

  • Third-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.176 Billion, a Decrease of 1.4 Percent on a Reported Basis, or 1.8 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $669 Million; Global Juvederm Net Revenues Were $222 Million

  • Successfully Completed Acquisition of Apogee Therapeutics, Deepening AbbVie's Robust Immunology Pipeline

  • Raises 2026 Adjusted Diluted EPS Guidance Range from $13.76 - $13.96 to $13.95 - $13.99, which Includes an Unfavorable Impact of $0.69 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2026 

  • Announces 2027 Dividend Increase of 5.2 Percent, Beginning with Dividend Payable in February 2027

NORTH CHICAGO, Ill., Oct. 30, 2026 /PRNewswire / -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2026.

"AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio," said Robert A. Michael, chairman and chief executive officer, AbbVie. "We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics. Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend."

Third-Quarter Results

  • Worldwide net revenues were $17.404 billion, an increase of 10.3 percent on a reported basis, or 10.5 percent on an operational basis.

  • Global net revenues from the immunology portfolio were $9.165 billion, an increase of 16.3 percent on a reported basis, or 16.6 percent on an operational basis.

    • Global Skyrizi net revenues were $5.776 billion, an increase of 22.7 percent on a reported basis, or 22.9 percent on an operational basis.
    • Global Rinvoq net revenues were $2.706 billion, an increase of 23.9 percent on a reported basis, or 24.3 percent on an operational basis.
    • Global Humira net revenues were $683 million, a decrease of 31.2 percent on a reported basis, or 30.6 percent on an operational basis.
  • Global net revenues from the neuroscience portfolio were $3.389 billion, an increase of 19.4 percent on a reported basis, or 19.5 percent on an operational basis.

    • Global Vraylar net revenues were $1.068 billion, an increase of 14.3 percent.
    • Global Botox Therapeutic net revenues were $1.080 billion, an increase of 9.8 percent.
    • Global Ubrelvy net revenues were $449 million, an increase of 26.9 percent.
    • Global Qulipta net revenues were $398 million, an increase of 38.2 percent on a reported basis, or 38.5 percent on an operational basis.
    • Global Vyalev net revenues were $286 million.
  • Global net revenues from the oncology portfolio were $1.696 billion, an increase of 0.8 percent on a reported basis, or 0.9 percent on an operational basis.

    • Global Venclexta net revenues were $803 million, an increase of 10.7 percent.
    • Global Imbruvica net revenues were $522 million, a decrease of 26.1 percent. 
    • Global Elahere net revenues were $224 million, an increase of 31.0 percent on a reported basis, or 31.2 percent on an operational basis.
  • Global net revenues from the aesthetics portfolio were $1.176 billion, a decrease of 1.4 percent on a reported basis, or 1.8 percent on an operational basis.

    • Global Botox Cosmetic net revenues were $669 million, an increase of 4.9 percent on a reported basis, or 4.1 percent on an operational basis.
    • Global Juvederm net revenues were $222 million, a decrease of 11.9 percent on a reported basis, or 11.8 percent on an operational basis.
  • On a GAAP basis, the gross margin ratio in the third quarter was 75.4 percent. The adjusted gross margin ratio was 85.1 percent.

  • On a GAAP basis, selling, general and administrative (SG&A) expense was 23.5 percent of net revenues. The adjusted SG&A expense was 21.2 percent of net revenues.

  • On a GAAP basis, research and development (R&D) expense was 14.7 percent of net revenues. The adjusted R&D expense was 13.9 percent of net revenues.

  • Acquired IPR&D and milestones expense was 1.2 percent of net revenues.

  • On a GAAP basis, the operating margin ratio in the third quarter was 36.0 percent. The adjusted operating margin ratio was 48.7 percent.

  • On a GAAP basis, net interest expense was $700 million. The adjusted net interest expense was $688 million.

  • On a GAAP basis, the tax rate in the quarter was 12.6 percent. The adjusted tax rate was 13.6 percent.

  • Diluted earnings per share (EPS) in the third quarter was $2.37 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $3.82. These results include an unfavorable impact of $0.11 per share related to acquired IPR&D and milestones expense.

Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. 

Recent Events

  • AbbVie announced it completed its acquisition of Apogee Therapeutics, deepening AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases. The acquisition includes zumilokibart, a late-stage, half-life extended monoclonal antibody targeting IL-13 for atopic dermatitis (AD), as well as APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP) in asthma.

  • AbbVie announced the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab) for subcutaneous (SC) induction in the treatment of moderately to severely active Crohn's disease (CD). The approval offers adult CD patients an additional option for induction of Skyrizi and is supported by positive data from the Phase 3 AFFIRM study. The FDA also approved an update to the U.S. prescribing information's warning and precautions for Skyrizi, across all indications, to allow healthcare providers to use clinical judgment when determining whether tuberculosis testing is needed. Additionally, AbbVie announced it submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi for SC induction in the treatment of adult patients with moderately to severely active CD.

  • AbbVie announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain IL-1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS). In the study, lutikizumab met the primary endpoint, achieving a significantly higher response rate of Hidradenitis Suppurativa Clinical Response 75 (HiSCR 75) at Week 16 compared with placebo and also met the majority of ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS flares over the first 16 weeks. Lutikizumab was generally well tolerated, with no new safety concerns identified. These data will be presented at a future medical congress. Additional data from this study, including results from a 36-week blinded extension period, are expected next year and will be used to support regulatory submissions for lutikizumab in HS in the second half of 2027.

  • At the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, AbbVie shared new Skyrizi and Rinvoq (upadacitinib) data which demonstrated disease control for patients living with inflammatory bowel disease (IBD). Highlights included new Phase 3 AFFIRM data which showed higher rates of clinical and endoscopic response in CD patients treated with SC Skyrizi versus placebo across all efficacy endpoints and observed subgroups; open-label extension analyses that demonstrated sustained endoscopic outcomes over time with Skyrizi, even in patients with complex disease characteristics and prior treatment exposure; and real-world studies that showed patients with advanced CD achieved disease control with Rinvoq, highlighting its potential benefit for difficult-to-treat patients.

  • At the 2026 United European Gastroenterology (UEG) Week, AbbVie showcased 20 presentations that underscored the breadth of its IBD research programs. Key disclosures included late-breaking results from the Phase 2a TARGET-CD trial for combination therapy ABBV-466 (Skyrizi + ABBV-382) which demonstrated higher endoscopic remission rates than either Skyrizi or ABBV-382 monotherapy at Week 12, the primary endpoint, with remission rates continuing to increase through Week 24 in patients with moderate to severe CD. AbbVie also presented long-term and real-world data for Skyrizi and Rinvoq that provided additional insight into clinical and endoscopic outcomes in moderately to severely active CD and ulcerative colitis (UC).

  • At the 2026 European Academy of Dermatology and Venereology (EADV) Congress, AbbVie presented data from 60 abstracts reflecting AbbVie's expanding portfolio across a wide spectrum of immune-mediated skin diseases. Highlights included late-breaking presentations from the Phase 3 Viti-Up-1 and Viti-Up-2 studies of Rinvoq in non-segmental vitiligo (NSV), which showed continued facial and total body repigmentation through week 76; primary results from the Phase 2 APEX Part B study evaluating zumilokibart in adult patients with moderate to severe AD, which showed all three dose regimens met the primary endpoint with significantly greater improvements in Eczema Area and Severity Index-75 (EASI-75) response rates versus placebo at week 16; and data showing how lutikizumab targets neutrophilic inflammation and fibroblast activation in HS.

  • AbbVie announced the FDA approved Juvmo (tavapadon) tablets as the only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease (PD). Taken once daily with or without levodopa therapy, Juvmo offers patients a differentiated approach to motor symptom control across the PD continuum. This approval is supported by the Phase 3 TEMPO program, which demonstrated significant improvements in daily functioning, increased "on" time without troublesome dyskinesia and a favorable safety profile.

  • AbbVie announced positive topline results from the Phase 3 LUNA study, which evaluated Qulipta (atogepant), a calcitonin gene-related peptide (CGRP) receptor antagonist, for the preventive treatment of menstrual migraine in adults. In the study, Qulipta demonstrated statistically significant reductions in migraine days associated with the menstrual period, meeting the primary and all eight ranked secondary endpoints versus placebo. Menstrual migraine is a recurrent, debilitating migraine pattern, with attacks occurring around or during the menstrual period. No treatment options are currently approved for menstrual migraine, underscoring the urgent need for care approaches specifically designed for this patient population.

  • At Psych Congress 2026, AbbVie presented new real-world data supporting the effectiveness of Vraylar (cariprazine), which showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder and bipolar I depression. These findings provide additional evidence that the benefits observed with Vraylar in clinical trials can also be achieved in routine practice, where patients often have more complex treatment needs. Vraylar is being co-developed by AbbVie and Gedeon Richter.

  • AbbVie announced submission of a Biologics License Application (BLA) to the FDA for etentamig, a next-generation BCMA x CD3 bispecific T-cell engager, for the treatment of patients living with relapsed/refractory multiple myeloma (RRMM). The submission is supported by positive results from the Phase 3 CERVINO study which demonstrated that etentamig achieved significant improvements in overall response rate (ORR, 74%) and progression-free survival (PFS, 60%) versus investigator's choice of standard available therapies in triple-class exposed adults with RRMM who had received at least two prior lines of therapy. Etentamig demonstrated low rates of cytokine release syndrome and fatal infections with monthly dosing from initiation following a single step-up dose. These results support the potential for etentamig treatment across a range of settings, including community-based care, offering a potentially differentiated treatment option for patients and providers.

  • AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration Epkinly (epcoritamab), a T-cell engaging bispecific antibody with SC administration, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). The trial demonstrated a statistically significant and clinically meaningful improvement in PFS in DLBCL patients, as the risk of disease progression or death was reduced by 51%. The safety profile of Epkinly when administered in combination with standard of care R-CHOP was generally well tolerated and consistent with the previously reported safety profiles of the individual agents. Based on the topline results, Genmab and AbbVie will engage global regulatory authorities. Epkinly is being co-developed by AbbVie and Genmab.

  • AbbVie announced the FDA granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A), a next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor, in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). These designations represent the first BTDs for Temab-A.

  • At the 23rd International Myeloma Society (IMS) Annual Meeting, AbbVie presented research demonstrating the breadth of its myeloma pipeline. Highlights included a plenary presentation featuring full results from the Phase 3 CERVINO study evaluating etentamig; as well as data from ABBV-2001, a trispecific T-cell engager; surzetoclax, a BCL-2 inhibitor; and combination approaches.

  • At the 2026 World Conference on Lung Cancer (WCLC), AbbVie shared new data showcasing its strategy aimed at building a lung cancer pipeline spanning next-generation immunotherapies, targeted ADCs and the potential for novel combination approaches. Presentations included clinical data from ABBV-1480, Temab-A and ABBV-706 programs across NSCLC and small cell lung cancer (SCLC). ABBV-1480 is developed in partnership with RemeGen.

  • At the 2026 European Society for Medical Oncology (ESMO), AbbVie presented new data across its solid tumor pipeline that underscored the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine. Data across multiple assets in various stages of development highlighted longer-term survival, combination and biomarker findings.

  • Allergan Aesthetics announced the FDA accepted for review its supplemental BLA for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. The submission is supported by two Phase 3 studies, demonstrating statistically significant improvements in MMP and patient satisfaction with treatment. If approved, Botox Cosmetic would become the first neurotoxin indicated for this condition in the U.S. and expand its portfolio to a fifth aesthetic indication.

  • At the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting, AbbVie announced detailed Phase 1 data for ABBV-295, a long-acting amylin analog being developed for the treatment of obesity. Data presented demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV-295 at dosing intervals beyond weekly administration, including every-other-week and monthly regimens. ABBV-295 also showed meaningful body weight reduction and a favorable tolerability profile at all evaluated dose levels, with topline results announced earlier this year. Findings support advancement of ABBV-295 into Phase 2 development for chronic weight management.

  • AbbVie announced an agreement with Valkai to apply advanced artificial intelligence (AI) across targeted areas of clinical development. The agreement is designed to strengthen integrated AI capabilities across clinical development to help accelerate the pace at which scientific innovation reaches patients.

  • AbbVie and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, announced a multi-year strategic relationship to accelerate the discovery and development of small molecule therapies in immunology, neuroscience and oncology. The strategic relationship will pursue programs with first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise.

Full-Year 2026 Outlook

AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026. The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted.

AbbVie does not provide a reconciliation of forward-looking non-GAAP financial measures, including adjusted diluted earnings per share to the most directly comparable generally accepted accounting principles in the United States (GAAP) financial measures because AbbVie is unable to predict with reasonable certainty, without unreasonable effort, the amount and timing of changes in fair value of contingent consideration, intangible asset impairments, acquisition and integration costs, litigation matters, income tax items and other adjustments. These items are uncertain, depend on various factors and could have a material impact on AbbVie's GAAP results for the guidance period.

Company Declares Dividend Increase of 5.2 Percent

AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.73 per share to $1.82 per share beginning with the dividend payable on February 16, 2027 to shareholders of record as of January 15, 2027. This reflects an increase of approximately 5.2 percent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. Since the company's inception in 2013, AbbVie has increased its quarterly dividend by 355 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on LinkedIn , Facebook , Instagram , X  and YouTube .

Conference Call

AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss our third-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the call will be available after 11:00 a.m. Central Time.

Non-GAAP Financial Results

Financial results for 2026 and 2025 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project," "estimate," "intend," "plan," "target," "may," "could" and "will," and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, drug pricing reform and government pricing programs, risks related to the use of artificial intelligence or other emerging technologies, and the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, tariffs and changes in U.S. and international trade policies, and other uncertainties and risks associated with global business operations. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made.

Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's most recently filed Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and in other documents AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Media: Investors:
Cat Langel Liz Shea
(708) 508-3524 (847) 935-2211
Todd Bosse
(847) 936-1182
Jeffrey Byrne
(847) 938-2923
AbbVie Inc.Key Product RevenuesQuarter Ended September 30, 2026(Unaudited)
% Change vs. 3Q25
Net Revenues (in millions) Reported Operational****a
U.S. Int'l. Total U.S. Int'l. Total Int'l. Total
NET REVENUES $13,333 $4,071 $17,404 10.5 % 9.8 % 10.3 % 10.6 % 10.5 %
Immunology 7,315 1,850 9,165 16.8 14.1 16.3 15.6 16.6
Skyrizi 5,019 757 5,776 22.9 21.6 22.7 23.2 22.9
Rinvoq 1,924 782 2,706 23.4 25.1 23.9 26.4 24.3
Humira 372 311 683 (39.9) (16.8) (31.2) (15.2) (30.6)
Neuroscience 2,939 450 3,389 19.3 20.0 19.4 20.7 19.5
Vraylar 1,064 4 1,068 14.3 43.5 14.3 46.0 14.3
Botox Therapeutic 912 168 1,080 10.5 5.8 9.8 5.6 9.8
Ubrelvy 438 11 449 27.3 13.9 26.9 15.0 26.9
Qulipta 333 65 398 32.1 80.2 38.2 82.3 38.5
Vyalev 154 132 286 >100.0 55.6 >100.0 57.2 >100.0
Other Neuroscience 38 70 108 (36.0) (15.3) (23.9) (14.6) (23.5)
Oncology 973 723 1,696 (5.7) 11.1 0.8 11.4 0.9
Venclexta 385 418 803 13.0 8.7 10.7 8.6 10.7
Imbruvicab 340 182 522 (33.0) (8.3) (26.1) (8.3) (26.1)
Elahere 166 58 224 9.6 >100.0 31.0 >100.0 31.2
Epkinlyc 43 65 108 >100.0 35.1 57.7 39.5 60.8
Other Oncology 39 — 39 >100.0 62.6 >100.0 62.6 >100.0
Aesthetics 723 453 1,176 (2.3) 0.1 (1.4) (1.0) (1.8)
Botox Cosmetic 388 281 669 2.4 8.6 4.9 6.5 4.1
Juvederm Collection 90 132 222 (6.3) (15.4) (11.9) (15.3) (11.8)
Other Aesthetics 245 40 285 (7.6) 5.5 (6.0) 6.5 (5.9)
Other Key Products 800 165 965 (3.5) (7.1) (4.1) (4.9) (3.7)
Mavyret 115 150 265 (21.2) (9.7) (15.1) (7.4) (13.9)
Creon 361 — 361 (2.2) n/m (2.2) n/m (2.2)
Linzess 324 15 339 3.2 31.1 4.2 31.8 4.2
a "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
b Reflects profit sharing for Imbruvica international revenues.
c Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.
n/m = not meaningful
AbbVie Inc.Key Product RevenuesNine Months Ended September 30, 2026(Unaudited)
% Change vs. 9M25
Net Revenues (in millions) Reported Operational****a
U.S. Int'l. Total U.S. Int'l. Total Int'l. Total
NET REVENUES $37,163 $12,233 $49,396 9.9 % 14.0 % 10.9 % 10.7 % 10.1 %
Immunology 19,809 5,432 25,241 14.9 19.7 15.9 16.5 15.2
Skyrizi 13,561 2,203 15,764 25.0 28.9 25.6 24.9 25.1
Rinvoq 5,094 2,256 7,350 20.4 32.8 23.9 29.2 22.9
Humira 1,154 973 2,127 (46.7) (13.8) (35.4) (15.2) (35.9)
Neuroscience 8,169 1,323 9,492 20.7 27.6 21.6 22.7 20.9
Vraylar 3,034 10 3,044 17.0 44.9 17.1 42.8 17.1
Botox Therapeutic 2,618 513 3,131 12.7 12.6 12.7 8.3 12.0
Ubrelvy 1,147 33 1,180 26.5 31.7 26.7 29.6 26.6
Qulipta 872 172 1,044 32.0 97.2 39.6 91.2 38.9
Vyalev 371 372 743 >100.0 70.9 >100.0 64.0 >100.0
Other Neuroscience 127 223 350 (38.0) (8.7) (22.0) (12.9) (24.3)
Oncology 2,791 2,186 4,977 (9.5) 14.6 (0.3) 11.5 (1.5)
Venclexta 1,095 1,249 2,344 12.4 12.8 12.6 7.9 10.0
Imbruvicab 1,009 601 1,610 (36.1) (2.9) (26.8) (2.9) (26.8)
Elahere 487 146 633 7.4 >100.0 24.5 >100.0 23.3
Epkinlyc 104 190 294 64.7 49.9 54.9 50.5 55.3
Other Oncology 96 — 96 >100.0 >100.0 >100.0 >100.0 >100.0
Aesthetics 2,188 1,456 3,644 0.5 4.3 2.0 0.9 0.7
Botox Cosmetic 1,159 906 2,065 6.9 13.1 9.5 8.7 7.6
Juvederm Collection 278 421 699 0.3 (9.8) (6.0) (11.8) (7.2)
Other Aesthetics 751 129 880 (8.1) 1.0 (6.9) (1.2) (7.2)
Other Key Products 2,377 518 2,895 3.3 (6.2) 1.5 (9.7) 0.8
Mavyret 431 480 911 (8.8) (7.8) (8.3) (11.2) (10.1)
Creon 1,067 — 1,067 (5.4) n/m (5.4) n/m (5.4)
Linzess 879 38 917 25.5 19.9 25.2 16.0 25.0
a "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
b Reflects profit sharing for Imbruvica international revenues.
c Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.
n/m = not meaningful
AbbVie Inc.Consolidated Statements of Earnings(Unaudited)
(in millions, except per share data) Third QuarterEnded September 30 Nine MonthsEnded September 30
2026 2025 2026 2025
Net revenues $    17,404 $    15,776 $    49,396 $    44,542
Cost of products sold 4,285 5,304 12,794 13,652
Selling, general and administrative 4,087 3,569 11,297 10,115
Research and development 2,567 2,319 7,383 6,517
Acquired IPR&D and milestones 216 2,680 1,251 3,751
Other operating income (18) — (18) (24)
Total operating costs and expenses 11,137 13,872 32,707 34,011
Operating earnings 6,267 1,904 16,689 10,531
Interest expense, net 700 667 2,024 1,972
Other expense, net 738 523 4,519 4,630
Earnings before income tax expense 4,829 714 10,146 3,929
Income tax expense 609 526 1,613 1,511
Net earnings 4,220 188 8,533 2,418
Net earnings attributable to noncontrolling interest 2 2 7 8
Net earnings attributable to AbbVie Inc. $      4,218 $        186 $      8,526 $      2,410
Diluted earnings per share attributable to AbbVie Inc. $        2.37 $       0.10 $        4.79 $        1.34
Adjusted diluted earnings per sharea $        3.82 $       1.86 $      10.12 $        7.29
Weighted-average diluted shares outstanding 1,772 1,772 1,772 1,772
a Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.
AbbVie Inc.Reconciliation of GAAP Reported to Non-GAAP Adjusted Information(Unaudited)
1.     Specified items impacted results as follows:
Quarter Ended September 30, 2026
(in millions, except per share data) Earnings Diluted
Pre-tax After-taxa EPS
As reported (GAAP) $        4,829 $        4,218 $          2.37
Adjusted for specified items:
Intangible asset amortization 1,669 1,419 0.79
Acquisition and integration costs 408 391 0.22
Change in fair value of contingent consideration 829 809 0.46
Other 131 (42) (0.02)
As adjusted (non-GAAP) $        7,866 $        6,795 $          3.82
a  Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Acquisition and integration costs primarily reflect costs related to the Apogee Therapeutics, Inc. acquisition.
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended September 30, 2026 included acquired IPR&D and milestone expense of$216 million on a pre-tax and $205 million on an after-tax basis, representing an unfavorable impact of $0.11 to both diluted EPS and adjusted diluted EPS.
2.     The impact of the specified items by line item was as follows:
Quarter Ended September 30, 2026
(in millions) Cost of products sold SG&A R&D Other operating income Interest expense, net Other expense, net
As reported (GAAP) $   4,285 $   4,087 $   2,567 $      (18) $    700 $     738
Adjusted for specified items:
Intangible asset amortization (1,669) — — — — —
Acquisition and integration costs (4) (250) (142) — (12) —
Change in fair value of contingent consideration — — — — — (829)
Other (11) (149) — 18 — 11
As adjusted (non-GAAP) $   2,601 $   3,688 $   2,425 $       — $    688 $      (80)
3.     The adjusted tax rate for the third quarter of 2026 was 13.6 percent, as detailed below:
Quarter Ended September 30, 2026
(dollars in millions) Pre-tax earnings Income taxes Tax rate
As reported (GAAP) $        4,829 $          609 12.6 %
Specified items 3,037 460 15.1 %
As adjusted (non-GAAP) $        7,866 $        1,069 13.6 %
AbbVie Inc.Reconciliation of GAAP Reported to Non-GAAP Adjusted Information(Unaudited)
1.     Specified items impacted results as follows:
Quarter Ended September 30, 2025
(in millions, except per share data) Earnings Diluted
Pre-tax After-taxa EPS
As reported (GAAP) $          714 $          186 $          0.10
Adjusted for specified items:
Intangible asset amortization 1,871 1,576 0.89
Intangible asset impairment 847 701 0.39
Acquisition and integration costs 212 207 0.12
Change in fair value of contingent consideration 776 755 0.43
Other (40) (119) (0.07)
As adjusted (non-GAAP) $        4,380 $        3,306 $          1.86
a  Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Intangible asset impairment reflects impairment charges of $847 million related to the Resonic and Durysta intangible assets. Acquisition and integration costsprimarily reflect costs related to the Capstan acquisition.
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended September 30, 2025 included acquired IPR&D and milestone expense of$2.7 billion on a pre-tax and after-tax basis, representing an unfavorable impact of $1.50 to both diluted EPS and adjusted diluted EPS.
2.     The impact of the specified items by line item was as follows:
Quarter Ended September 30, 2025
(in millions) Cost of products sold SG&A R&D Other expense, net
As reported (GAAP) $   5,304 $   3,569 $   2,319 $     523
Adjusted for specified items:
Intangible asset amortization (1,871) — — —
Intangible asset impairment (847) — — —
Acquisition and integration costs (5) (144) (63) —
Change in fair value of contingent consideration — — — (776)
Other (34) (13) — 87
As adjusted (non-GAAP) $   2,547 $   3,412 $   2,256 $    (166)
3.     The adjusted tax rate for the third quarter of 2025 was 24.5 percent, as detailed below:
Quarter Ended September 30, 2025
(dollars in millions) Pre-tax earnings Income taxes Tax rate
As reported (GAAP) $          714 $          526 73.7 %
Specified items 3,666 546 14.9 %
As adjusted (non-GAAP) $        4,380 $       1,072 24.5 %
AbbVie Inc.Reconciliation of GAAP Reported to Non-GAAP Adjusted Information(Unaudited)
1.     Specified items impacted results as follows:
Nine Months Ended September 30, 2026
(in millions, except per share data) Earnings Diluted
Pre-tax After-taxa EPS
As reported (GAAP) $       10,146 $        8,526 $          4.79
Adjusted for specified items:
Intangible asset amortization 5,106 4,353 2.45
Acquisition and integration costs 431 410 0.23
Change in fair value of contingent consideration 4,734 4,613 2.60
Other 631 95 0.05
As adjusted (non-GAAP) $       21,048 $       17,997 $        10.12
a  Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Acquisition and integration costs primarily reflect costs related to the Apogee Therapeutics, Inc. acquisition.
Reported GAAP earnings and adjusted non-GAAP earnings for the nine months ended September 30, 2026 included acquired IPR&D and milestones expense of$1.3 billion on a pre-tax and $1.2 billion on an after-tax basis, representing an unfavorable impact of $0.69 to both diluted EPS and adjusted diluted EPS.
2.     The impact of the specified items by line item was as follows:
Nine Months Ended September 30, 2026
(in millions) Cost of products sold SG&A R&D Other operating income Interest expense, net Other expense, net
As reported (GAAP) $  12,794 $  11,297 $    7,383 $      (18) $  2,024 $    4,519
Adjusted for specified items:
Intangible asset amortization (5,106) — — — — —
Acquisition and integration costs (7) (257) (155) — (12) —
Change in fair value of contingent consideration — — — — — (4,734)
Other (20) (377) (221) 18 — (31)
As adjusted (non-GAAP) $    7,661 $  10,663 $    7,007 $        — $  2,012 $     (246)
3.     The adjusted tax rate for the first nine months of 2026 was 14.5 percent, as detailed below:
Nine Months Ended September 30, 2026
(dollars in millions) Pre-tax earnings Income taxes Tax rate
As reported (GAAP) $       10,146 $        1,613 15.9 %
Specified items 10,902 1,431 13.1 %
As adjusted (non-GAAP) $       21,048 $        3,044 14.5 %
AbbVie Inc.Reconciliation of GAAP Reported to Non-GAAP Adjusted Information(Unaudited)
1.     Specified items impacted results as follows:
Nine Months Ended September 30, 2025
(in millions, except per share data) Earnings Diluted
Pre-tax After-taxa EPS
As reported (GAAP) $        3,929 $        2,410 $          1.34
Adjusted for specified items:
Intangible asset amortization 5,593 4,721 2.67
Intangible asset impairment 847 701 0.39
Acquisition and integration costs 273 256 0.14
Change in fair value of contingent consideration 5,089 4,941 2.79
Other 52 (75) (0.04)
As adjusted (non-GAAP) $       15,783 $       12,954 $          7.29
a  Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Intangible asset impairment reflects impairment charges of $847 million related to the Resonic and Durysta intangible assets. Acquisition and integration costsprimarily reflect costs related to the Capstan acquisition.
Reported GAAP earnings and adjusted non-GAAP earnings for the nine months ended September 30, 2025 included acquired IPR&D and milestones expense of$3.8 billion on a pre-tax and $3.6 billion on an after-tax basis, representing an unfavorable impact of $2.05 to both diluted EPS and adjusted diluted EPS.
2.     The impact of the specified items by line item was as follows:
Nine Months Ended September 30, 2025
(in millions) Cost of products sold SG&A R&D Other operating income Other expense, net
As reported (GAAP) $ 13,652 $ 10,115 $   6,517 $     (24) $   4,630
Adjusted for specified items:
Intangible asset amortization (5,593) — — — —
Intangible asset impairment (847) — — — —
Acquisition and integration costs (10) (171) (92) — —
Change in fair value of contingent consideration — — — — (5,089)
Other (126) (13) (3) 24 66
As adjusted (non-GAAP) $   7,076 $   9,931 $   6,422 $      — $    (393)
3.     The adjusted tax rate for the first nine months of 2025 was 17.9 percent, as detailed below:
Nine Months Ended September 30, 2025
(dollars in millions) Pre-tax earnings Income taxes Tax rate
As reported (GAAP) $        3,929 $        1,511 38.5 %
Specified items 11,854 1,310 11.1 %
As adjusted (non-GAAP) $       15,783 $        2,821 17.9 %

SOURCE AbbVie

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc. Her resignation as a director is not the result of any dispute or disagreement with AbbVie on any matter relating to the operations, policies or practices of AbbVie.

Prompts

AbbVie Inc. (ticker ABBV), listed in United States.

Company History

Date Change Detail
May 4, 2015 Acquired Acquired Pharmacyclics Inc (CIK 949699). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding AbbVie Inc.

ETF Weight in ETF Shares Market value As of
MEDX 8.85% 6,712 $ 1.689M Jun 30, 2026
JDOC 8.47% 2,858 $ 836.88K Nov 17, 2026
DUNK 6.43% 36,202 $ 10.663M Nov 17, 2026
PSIL 6.20% 8,071 $ 2.363M Nov 17, 2026
ROPE 5.59% 4,721 $ 1.38M Nov 18, 2026
BMED 5.00% 2,431 $ 716.051K Nov 16, 2026
UDI 4.37% 706 $ 177.658K Jun 30, 2026
PINK 4.34% 49,605 $ 14.525M Nov 17, 2026
DIVN 4.22% 50,463 $ 12.94M Aug 31, 2026
AGQI 4.16% 7,225 $ 2.128M Nov 16, 2026
TGLR 4.13% 6,220 $ 1.561M Jul 31, 2026
BDVG 4.11% 2,213 $ 556.879K Jun 30, 2026
DIVL 3.68% 8,786 $ 2.211M Jun 30, 2026
DIVZ 3.49% 37,043 $ 9.322M Jun 30, 2026
DIVE 3.48% 5,912 $ 1.741M Nov 17, 2026
PJFV 3.42% 31,202 $ 9.137M Nov 18, 2026
USMC 3.39% 470,441 $ 118.382M Jun 30, 2026
RJDI 3.37% 13,426 $ 3.379M Jun 30, 2026
DSTL 3.35% 282,972 $ 71.207M Jun 30, 2026
CANC 3.32% 27,338 $ 7.01M Aug 31, 2026
DIVS 3.30% 5,045 $ 1.269M Jun 30, 2026
FDV 3.29% 115,545 $ 28.995M Jul 31, 2026
BRIF 3.01% 18,454 $ 4.644M Jun 30, 2026
DIVY 2.94% 3,005 $ 885.123K Nov 17, 2026
ABFL 2.85% 59,784 $ 15.002M Jul 31, 2026
PAYR 2.78% 6,332 $ 1.589M Jul 31, 2026
FLCV 2.77% 15,059 $ 3.861M Aug 31, 2026
CGCV 2.73% 227,874 $ 67.12M Nov 16, 2026
BBLU 2.73% 46,084 $ 13.49M Nov 18, 2026
GEND 2.72% 526 $ 131.994K Jul 31, 2026
MODL 2.69% 109,512 $ 27.558M Jun 30, 2026
SAMT 2.60% 90,587 $ 22.795M Jun 30, 2026
ACVU 2.53% 23,975 $ 0.00 Nov 18, 2026
MKTN 2.44% 10,345 $ 2.603M Jun 30, 2026
HRTS 2.35% 5,088 $ 1.305M Aug 31, 2026
SWP 2.28% 13,323 $ 3.416M Aug 31, 2026
CGDG 2.22% 452,438 $ 133.266M Nov 16, 2026
FLCC 2.12% 11,003 $ 2.821M Aug 31, 2026
LVDS 2.10% 8,561 $ 2.507M Nov 17, 2026
FDIV 2.08% 4,854 $ 1.218M Jul 31, 2026
AVIE 2.06% 1,162 $ 342.267K Nov 16, 2026
CAPE 2.03% 19,271 $ 4.849M Jun 30, 2026
JGLO 1.97% 389,642 $ 114.095M Nov 17, 2026
PVAL 1.94% 1,067,225 $ 273.658M Aug 31, 2026
JDIV 1.93% 811 $ 237.477K Nov 17, 2026
CGDV 1.89% 2,455,160 $ 723.167M Nov 16, 2026
THOR 1.84% 1,700 $ 435.914K Aug 31, 2026
SCLZ 1.84% 1,432 $ 360.348K Jun 30, 2026
GQGU 1.83% 40,849 $ 10.279M Jun 30, 2026
JAVA 1.81% 460,989 $ 134.987M Nov 17, 2026
JEPI 1.76% 2,772,363 $ 811.803M Nov 17, 2026
LOWV 1.75% 13,950 $ 3.577M Aug 31, 2026
LCDS 1.70% 926 $ 271.151K Nov 17, 2026
JOYT 1.65% 6,702 $ 1.962M Nov 17, 2026
WCAP 1.64% 3,990 $ 1.001M Jul 31, 2026
MFSV 1.62% 38,077 $ 9.764M Aug 31, 2026
MEDI 1.60% 2,420 $ 712.569K Nov 12, 2026
INFO 1.60% 49,804 $ 14.694M Nov 13, 2026
ALRG 1.59% 532 $ 133.5K Jul 31, 2026
FTQI 1.57% 51,259 $ 15.098M Nov 16, 2026
OEI 1.55% 2,864 $ 718.692K Jul 31, 2026
VUS 1.48% 1,056 $ 264.993K Jul 31, 2026
GROZ 1.46% 6,589 $ 1.69M Aug 31, 2026
JSTC 1.38% 13,822 $ 4.071M Nov 17, 2026
FEAC 1.34% 1,374 $ 345.753K Jun 30, 2026
SIXA 1.33% 25,749 $ 7.582M Nov 12, 2026
HELO 1.28% 208,322 $ 61.001M Nov 17, 2026
BIGY 1.27% 1,212 $ 356.995K Nov 17, 2026
BDYN 1.22% 124,483 $ 36.666M Nov 16, 2026
FTHI 1.22% 104,860 $ 30.887M Nov 16, 2026
VSLU 1.22% 26,439 $ 6.653M Jun 30, 2026
XMAG 1.21% 8,853 $ 2.607M Nov 13, 2026
DIVD 1.20% 1,122 $ 330K Nov 18, 2026
QDVO 1.19% 34,797 $ 8.756M Jun 30, 2026
JUSA 1.18% 35,170 $ 10.298M Nov 17, 2026
FELC 1.16% 362,362 $ 91.185M Jun 30, 2026
NBGX 1.15% 669 $ 171.545K Aug 31, 2026
BKDV 1.15% 84,302 $ 21.155M Jul 31, 2026
ROE 1.14% 9,632 $ 2.82M Nov 18, 2026
LGRO 1.10% 6,114 $ 1.568M Aug 31, 2026
UPSD 1.10% 5,134 $ 1.288M Jul 31, 2026
RJVI 1.09% 595 $ 149.726K Jun 30, 2026
FELG 1.08% 242,931 $ 61.131M Jun 30, 2026
MPLY 1.06% 674 $ 169.134K Jul 31, 2026
HIDV 1.05% 8,375 $ 2.148M Aug 31, 2026
PHEQ 1.04% 5,782 $ 1.455M Jun 30, 2026
LQAI 1.03% 78 $ 22.967K Nov 12, 2026
SFGV 1.03% 40,814 $ 11.95M Nov 18, 2026
ACLC 1.02% 12,964 $ 3.324M Aug 31, 2026
FYEE 0.99% 8,650 $ 2.171M Jul 31, 2026
GINX 0.99% 4,117 $ 1.056M Aug 31, 2026
NDOW 0.97% 2,679 $ 674.144K Jun 30, 2026
ACVF 0.96% 5,854 $ 1.469M Jul 31, 2026
PEPS 0.91% 1,045 $ 262.964K Jun 30, 2026
ENHU 0.91% 289 $ 85.125K Nov 16, 2026
FHEQ 0.89% 33,045 $ 8.292M Jul 31, 2026
LDRX 0.87% 8,645 $ 2.217M Aug 31, 2026
NQLT 0.87% 1,664 $ 426.683K Aug 31, 2026
FTLS 0.87% 76,695 $ 0.00 Nov 16, 2026
ACIO 0.84% 78,510 $ 19.701M Jul 31, 2026